The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors through allosteric signaling.

“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are involved in a ...

GPCRs are the targets for around one third of all approved drugs 1. Yet such medicines act on only a handful of the 800+ known GPCRs. A wave of biomedical progress in the early 21 st century thrust ...

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Recently, the importance of drug design based not only on the affinity or binding energy between a compound and its target protein, but also on its components, enthalpy, and entropy, has been ...

In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

Cone snails deploy sophisticated venom cocktails to paralyse prey. Anthony King talks to the researchers harnessing these ...

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS ...